These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 6327515)
41. [The role of combination therapy in the treatment of arterial hypertension]. Tsareva VM; Khoziainova NIu Kardiologiia; 2009; 49(6):15-8. PubMed ID: 19656089 [No Abstract] [Full Text] [Related]
42. Effect of enalapril (MK-421), an orally active angiotensin I converting enzyme inhibitor, on blood pressure, active and inactive plasma renin, urinary prostaglandin E2, and kallikrein excretion in conscious rats. Schiffrin EL; Gutkowska J; Thibault G; Genest J Can J Physiol Pharmacol; 1984 Jan; 62(1):116-23. PubMed ID: 6143602 [TBL] [Abstract][Full Text] [Related]
43. Effects of the new oral angiotensin converting enzyme inhibitor MK-421 in human hypertension. Gavras H; Biollaz J; Waeber B; Brunner HR; Gavras I; Davies RO Clin Exp Hypertens A; 1982; 4(1-2):303-14. PubMed ID: 6280900 [TBL] [Abstract][Full Text] [Related]
44. The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: different effects of enalapril and hydrochlorothiazide. Dahlöf B; Hansson L J Intern Med; 1993 Sep; 234(3):271-9. PubMed ID: 8354977 [TBL] [Abstract][Full Text] [Related]
45. Acute and chronic hemodynamic effects of enalapril (MK-421) in congestive heart failure. Dickstein K; Søyland E; Gundersen T; Abrahamsen AM; Kjekshus J Int J Cardiol; 1984 Oct; 6(4):445-58. PubMed ID: 6092286 [TBL] [Abstract][Full Text] [Related]
46. Comparison of the cardiac and hemodynamic effects of lisinopril and atenolol in patients with hypertension: therapeutic implications. Zusman RM; Christensen DM; Higgins J; Boucher CA J Cardiovasc Pharmacol; 1992 Aug; 20(2):216-22. PubMed ID: 1381012 [TBL] [Abstract][Full Text] [Related]
47. Systolic blood pressure responses to enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) and hydrochlorothiazide in conscious Dahl salt-sensitive and salt-resistant rats. Sharma JN; Fernandez PG; Kim BK; Triggle CR Can J Physiol Pharmacol; 1984 Jul; 62(7):846-9. PubMed ID: 6093967 [TBL] [Abstract][Full Text] [Related]
48. Antihypertensive effect of MK-421 in rats. Role of the renal kallikrein-kinin system. Yasujima M; Abe K; Tanno M; Kasai Y; Tajima J; Seino M; Chiba S; Sato K; Goto T; Omata K Hypertension; 1984; 6(2 Pt 1):229-35. PubMed ID: 6327517 [TBL] [Abstract][Full Text] [Related]
49. Comparison of increase in the enalapril dose and addition of hydrochlorothiazide as second-step treatment of hypertensive patients not controlled by enalapril alone. Sassano P; Chatellier G; Billaud E; Corvol P; Ménard J J Cardiovasc Pharmacol; 1989 Feb; 13(2):314-9. PubMed ID: 2468963 [TBL] [Abstract][Full Text] [Related]
51. Time course of vascular structural changes during and after short-term antihypertensive treatment. Hale TM; Shoichet MJ; Bushfield TL; Adams MA Hypertension; 2003 Aug; 42(2):171-6. PubMed ID: 12810756 [TBL] [Abstract][Full Text] [Related]
52. Enalapril in the treatment of hypertension with renal artery stenosis. Hodsman GP; Brown JJ; Cumming AM; Davies DL; East BW; Lever AF; Morton JJ; Murray GD; Robertson I; Robertson JI Br Med J (Clin Res Ed); 1983 Nov; 287(6403):1413-7. PubMed ID: 6315126 [TBL] [Abstract][Full Text] [Related]
53. Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system. Dahlöf B; Herlitz H; Aurell M; Hansson L Am J Hypertens; 1992 Dec; 5(12 Pt 1):900-11. PubMed ID: 1337459 [TBL] [Abstract][Full Text] [Related]
54. Oral therapy with combined enalapril, prazosin and hydrochlorothiazide in the acute treatment of severe hypertension in Nigerians. Ajayi AA; Afolabi MA; Balogun MO; Adigun AQ; Ajayi OE; Akintomide AO Eur J Clin Pharmacol; 1996; 51(1):45-8. PubMed ID: 8880050 [TBL] [Abstract][Full Text] [Related]
55. Comparative effectiveness of antihypertensive drugs prescribed in Ethiopian healthcare practice: A pilot prospective, randomized, open label study. Mengesha HG; Welegerima AH; Hadgu A; Temesgen H; Otieno MG; Tsegay K; Fisseha T; Getachew S; Merha Z; Tewodros H; Dabessa J; Gebreegzabher B; Petrucka P PLoS One; 2018; 13(9):e0203166. PubMed ID: 30204768 [TBL] [Abstract][Full Text] [Related]
56. Treatment of mild to moderate hypertension with or without the converting enzyme inhibitor enalapril. Results of a six-month double-blind trial. Sassano P; Chatellier G; Billaud E; Alhenc-Gelas F; Corvol P; Ménard J Am J Med; 1987 Aug; 83(2):227-35. PubMed ID: 3039842 [TBL] [Abstract][Full Text] [Related]
57. Time course and effect of sodium intake on vascular and hormonal responses to enalapril (MK 421) in normal subjects. Shoback DM; Williams GH; Swartz SL; Davies RO; Hollenberg NK J Cardiovasc Pharmacol; 1983; 5(6):1010-8. PubMed ID: 6196548 [TBL] [Abstract][Full Text] [Related]
58. Relation of cardiovascular response to the hypotensive effect of metoprolol. Fouad FM; Tarazi RC; Bravo EL Am Heart J; 1982 Oct; 104(4 Pt 1):803-11. PubMed ID: 7124594 [TBL] [Abstract][Full Text] [Related]